Bcl11a Inhibitors
Chemical inhibitors of Bcl11a function by impeding the activity of various signaling pathways and enzymes that regulate or modify the protein's activity. Staurosporine serves as a broad-spectrum protein kinase inhibitor, which can lead to a reduction in the phosphorylation of Bcl11a, thereby decreasing its activity. Similarly, Thapsigargin disrupts calcium homeostasis by inhibiting the sarco/endoplasmic reticulum Ca2+ ATPase (SERCA), which causes an increase in cytosolic calcium levels. This elevation in calcium can activate phosphatases that can dephosphorylate Bcl11a, resulting in diminished activity. Another inhibitor, JQ1, targets the bromodomain-containing protein 4 (BRD4), a component of the transcriptional machinery that affects Bcl11a function. By inhibiting BRD4, JQ1 can disrupt the recruitment of transcriptional apparatus necessary for Bcl11a's activity.
Ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, can alter Bcl11a's function by modulating the downstream signaling events that Bcl11a is involved in. PD173074, which inhibits fibroblast growth factor receptor (FGFR), affects the signaling cascades that regulate Bcl11a, leading to a decrease in its function. Rapamycin, an mTOR inhibitor, impacts the PI3K/AKT/mTOR pathway, which is significant for Bcl11a regulation. Inhibition by rapamycin can lead to a decrease in Bcl11a's function through changes in downstream signaling. PP2, an inhibitor of Src family kinases, and Imatinib, which targets tyrosine kinases such as BCR-ABL, c-KIT, and PDGFR, also decrease Bcl11a function by altering the associated signaling pathways. Additionally, Trichostatin A, an HDAC inhibitor, can modify gene expression in pathways that regulate Bcl11a. Y-27632, a ROCK inhibitor, can disrupt cytoskeletal organization and cell adhesion, influencing Bcl11a function. Finally, SP600125 and SB431542, which inhibit c-Jun N-terminal kinase (JNK) and the TGF-beta receptor kinase respectively, can lead to reduced Bcl11a activity by modifying the respective stress response, apoptosis, and cellular differentiation signaling pathways.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent inhibitor of a wide range of protein kinases. Bcl11a is known to be regulated by phosphorylation. Through the inhibition of kinases that phosphorylate Bcl11a, Staurosporine can lead to a reduction in Bcl11a's functional activity. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
Thapsigargin inhibits the sarco/endoplasmic reticulum Ca2+ ATPase (SERCA), leading to an increase in cytosolic calcium levels. Elevated calcium can activate various calcium-dependent phosphatases, which can dephosphorylate Bcl11a, thereby inhibiting its function. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $226.00 $846.00 | 1 | |
JQ1 inhibits bromodomain-containing protein 4 (BRD4), which is a part of the transcriptional regulation that can impact Bcl11a activity. By inhibiting BRD4, JQ1 may disrupt the recruitment of transcriptional machinery necessary for the full functional activity of Bcl11a. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $153.00 | 5 | |
Ibrutinib inhibits Bruton's tyrosine kinase (BTK), which can impact signaling pathways that intersect with those regulated by Bcl11a. The inhibition of BTK can reduce the functional activity of Bcl11a by influencing downstream signaling events. | ||||||
PD173074 | 219580-11-7 | sc-202610 sc-202610A sc-202610B | 1 mg 5 mg 50 mg | $46.00 $140.00 $680.00 | 16 | |
PD173074 is an inhibitor of the fibroblast growth factor receptor (FGFR), which is involved in numerous signaling cascades that can intersect with pathways regulated by Bcl11a. Inhibiting FGFR can lead to a decrease in Bcl11a functional activity by altering these signaling cascades. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR (mammalian target of rapamycin), which is part of the PI3K/AKT/mTOR pathway, a signaling pathway that can regulate Bcl11a activity. Inhibiting mTOR may result in decreased Bcl11a function due to altered downstream signaling. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is an inhibitor of Src family kinases, which are involved in a variety of signaling pathways that can regulate Bcl11a activity. Inhibition of Src kinases can lead to decreased Bcl11a function through changes in these signaling pathways. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Imatinib is a tyrosine kinase inhibitor that targets BCR-ABL, c-KIT, and PDGFR. Kinases like c-KIT are involved in signaling pathways that can regulate Bcl11a. By inhibiting these kinases, Imatinib may indirectly inhibit Bcl11a function by altering signaling pathways. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A is an inhibitor of histone deacetylases (HDACs), which can affect the chromatin state and gene expression profiles. HDACs can regulate genes that are in the same pathways as Bcl11a or that interact with Bcl11a. Inhibiting HDACs can inhibit Bcl11a function by altering gene expression in these pathways. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 is an inhibitor of ROCK (Rho-associated protein kinase), which can affect cytoskeletal organization and cell adhesion pathways. These pathways can intersect with signaling cascades that regulate Bcl11a's function. By inhibiting ROCK, Y-27632 can lead to an inhibition of Bcl11a's functional activity. | ||||||